New 'Cicada' COVID Subvariant Detected Across Multiple Nations: What You Need to Know
If you have encountered the term "Cicada variant" in recent news or social media discussions, you are certainly not alone. This nickname has gained traction, partly due to its dramatic sound and partly because of public vigilance regarding any new developments in the COVID-19 pandemic. However, it is crucial to clarify that "Cicada" is not an official scientific designation. Instead, it is an informal label applied to a newer subvariant of the SARS-CoV-2 virus, which researchers are actively investigating.
Understanding the Nature of Viral Mutations
Viruses naturally mutate over time, and SARS-CoV-2, the pathogen responsible for COVID-19, has continued to evolve through successive waves. The so-called Cicada variant is believed to be a descendant within the Omicron lineage. This means it is not an entirely novel threat but rather a branch with specific genetic modifications that warrant monitoring.
Global Spread and Detection Patterns
The highly divergent SARS-CoV-2 subvariant, scientifically identified as BA.3.2, was first detected in a respiratory sample collected on November 22, 2024, in South Africa, according to the U.S. Centers for Disease Control and Prevention (CDC). In a report released on March 19, 2026, the CDC provided detailed insights into its dissemination.
As of February 11, 2026, BA.3.2 had been reported in 23 countries worldwide. Detections began to increase notably in September 2025. In the United States, this subvariant has been identified through multiple sources:
- Nasal swabs from four travelers
- Three airplane wastewater samples
- Clinical samples from five patients
- 132 wastewater samples collected from 25 U.S. states
This data underscores the variant's presence across diverse geographical regions and detection methods.
Assessing the Threat Level: Expert Perspectives
Dr. Santosh Kumar Agrawal, Director of Internal Medicine at Yatharth Super Speciality Hospital in Faridabad Sector-88, offered a professional assessment of the current situation. "The current BA.3.2 cicada subvariant is not regarded as an eminent threat at this time," he stated. This subvariant is classified as a Variant Under Monitoring and not a Variant of Concern.
Dr. Agrawal elaborated that the majority of cases associated with this subvariant appear to be mild or moderate in severity. However, he cautioned that due to numerous genetic variations between BA.3.2 and earlier BA.3 subvariants, this newer strain may possess enhanced capabilities for transmission or reinfection.
"As such, individuals in the highest at-risk groups—including the elderly, pregnant women, and those who are immunocompromised—should remain aware of the potential for this variant to spread easily," he advised, emphasizing the importance of vigilance among vulnerable populations.
Symptom Profile of the BA.3.2 Subvariant
According to Dr. Agrawal, the symptoms associated with the BA.3.2 subvariant are generally similar to those observed with earlier COVID-19 strains. However, he highlighted a distinctive hallmark: a severe and painful sore throat that has been notably linked to this particular variant.
Additional symptoms commonly reported include:
- Runny and blocked nasal passages
- Persistent dry coughing
- Fever accompanied by chills and fatigue
- Muscle pains or headaches
- Loss of sense of taste and smell
- In some instances, mild difficulty breathing
This symptom profile aligns with typical respiratory infections but with the noted emphasis on throat discomfort, which may aid in clinical identification.
Conclusion: Staying Informed and Prepared
While the Cicada subvariant represents another step in the ongoing evolution of COVID-19, current expert analysis suggests it does not pose an immediate, severe threat to the general population. Its classification as a Variant Under Monitoring indicates that health authorities are tracking its development closely without raising alarm bells. Public health recommendations remain consistent: stay informed through reliable sources, practice good hygiene, and consider protective measures, especially if you belong to high-risk groups. As research continues, further updates will be essential for adapting responses to this ever-changing viral landscape.
